Metastatic breast cancer to the liver is considered incurable. Though many patients with liver metastases may enjoy response to chemo-, immuno- and hormonal therapy, those so inflicted rarely remain disease-free from the time of diagnosis for longer than 6-11 months. New laboratory and clinical research identified that cross-talk between activation of the epidermal growth factor family of tyrosine kinase transduction pathways (EGF/HER2) and estrogen receptor (ER) activation plays a role in resistance to hormonal therapy.
A 59-year-old woman with a 4.5-cm invasive ductal, ER-positive/PR-negative, grade III adenocarcinoma of the breast was treated with mastectomy. Staging revealed biopsy-proven liver metastases. Surgery was immediately followed with vinorelbine, trastuzumab, tamoxifen and exemestane. The patient underwent a bone scan and PET/CT documented complete remission. She has remained in complete remission for 7 years. It is proposed that a possible mechanism for prolonged remission of stage IV breast cancer in this patient may be related to suppression of EGF/HER2 by trastuzumab, thus inhibiting cross-talk-associated tamoxifen/estrogen withdrawal resistance.
AliS., CoombesR.C.: Endocrine-responsive breast cancer and strategies for combating resistance.Nat Rev Cancer, 2: 101–112, 2002.
5.
CampbellR.A., Bhat-NakshatriP., PatelN.M., ConstantinidouD., AliS., NakshatriH.: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance.J Biol Chem, 276: 9817–9824, 2001.
ShouJ., MassarwehS., OsborneC.K., WakelingA.E., AliS., WeissH., SchiffR.: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu. Cross-talk in ER/HER2-positive breast cancer.J Natl Cancer Inst, 96: 926–935, 2004.
8.
ChungY.L., SheuM.L., YangS.C., LinC.H., YenS.H.: Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer.Int J Cancer, 97: 306–312, 2002.
9.
KonecnyG., PaulettiG., PegramM., UntchM., DandekarS., AguilarZ., WilsonC., RongH-M, BauerfeindI., FelberM., WangH-J, BerytM., SeshadriR., HeppH., SlamonD.J.: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.J Natl Cancer Inst, 95: 142–153, 2003.
10.
OsborneC.K., BardouV., HoppT.A., ChamnessG.C., HilsenbeckS.G., FuquaS.A., WongJ., AllredD.C., ClarkG.M., SchiffR.: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.J Natl Cancer Inst, 95: 338–340, 2003.
11.
SchiffR., OsborneK.C.: Endocrinology and hormone therapy in breast cancer: New insight into estrogen receptor-function and its implication for endocrine therapy resistance in breast cancer.Breast Cancer Res, 7: 205–211, 2005.
12.
PedramA., RazandiM., LevinE.R.: Nature of functional estrogen receptors at the plasma membrane.Mol Endocrinol, 20: 1996–2009, 2006.
13.
WyckoffM.H., ChamblissK.L., MineoC., YuhannaI.S., MendelsohnM.E., MumbyS.M., ShaulP.W.: Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through G alpha(i).J Biol Chem, 276: 27071–27076, 2001.
14.
VogelC., CobleighM.A., TripathyD., GutheilJ.C., HarrisL.N., FehrenbacherL., SlamonD.J., MurphyM., NovotnyW.F., BurchmoreM., ShakS., StewartS.J.: First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.Eur J Cancer, 37(Suppl 1): S25–29, 2001.
15.
RasmussenB.B., ReganM.M., LykkesfeldtA.E., Dell'OrtoP., Del CurtoB., HenriksenK.L., MastropasquaM.G., PriceK.N., MéryE., Lacroix-TrikiM., BrayeS., AltermattH.J., GelberR.D., Castiglione-GertschM., GoldhirschA., GustersonB.A., ThürlimannB., CoatesA.S., VialeG.for the BIG 1-98 Collaborative and International Breast Cancer Study Groups: Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.Lancet Oncol, 9: 23–28, 2008.
16.
ChanA.: A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer.Ann Oncol, 18: 1152–1158, 2007.
17.
MunzoneE., CuriglianoG., RoccaA., BonizziG., RenneG., GoldhirschA., NolèF.: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.Breast Cancer Res, 8: R4, 2006.
18.
MackeyJ.R., KaufmanB., ClemensM., BapsyP.P., VaidA., WardleyA., TjulandinS., JahnM., LehleM., JonesA.: Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium (abstract 3).Breast Cancer Res Treat, 100(Suppl 1): S5, 2006.
19.
ArpinoG., GutierrezC., WeissH., RimawiM., MassarwehS., BharwaniL., De PlacidoS., OsborneC.K., SchiffR.: Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER targeted therapy.J Natl Cancer Inst, 99: 694–705, 2007.
20.
DowsettM., CuzickJ., WaleC., HowellT., HoughtonJ., BaumM.: Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis generating study.J Clin Oncol, 23: 7512–7217, 2005.
21.
ArpinoG., WeissH., LeeA.V., SchiffR., De PlacidoS., OsborneK.C., ElledgeR.M.: Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.J Natl Cancer Inst, 97: 1254–1261, 2005.
